Physician profile
Mark R Lee
NPI 1669400172
$6,633.62
in general payments reported to CMS, 2019-2025
22 companies · $988 in 2025
The $988 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $595 · 2021: $1,238 · 2022: $958 · 2023: $829 · 2024: $867 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495 · Entertainment: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.58 |
| Entertainment | $190.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,882.67 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $794.29 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Optos, INC. | $688.01 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $404.24 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $353.28 | 2019-2021 | |
| Topcon Healthcare, INC. | $322.82 | 2020-2021 | |
| Maculogix, INC. | $289.91 | 2019-2020 | |
| Sight Sciences, INC. | $265.79 | 2021-2023 | Tearcare System |
| Lombart Brothers, INC. | $251.67 | 2025 | Opd-III |
| Eyevance Pharmaceuticals LLC | $212.38 | 2019 | |
| Bausch & Lomb Americas INC. | $155.11 | 2022-2025 | Infuse |
| Sun Pharmaceutical Industries INC. | $150.04 | 2019-2021 | |
| Allergan, INC. | $147.03 | 2020-2022 | |
| Abbvie INC. | $144.37 | 2022-2024 | |
| Shire North American Group INC | $124.97 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $120.06 | 2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $87.42 | 2021 | |
| Visionix USA, INC | $78.83 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $58.42 | 2019-2020 | |
| Oyster Point Pharma, INC. | $43.48 | 2023-2024 | Tyrvaya |
| Dompe US, INC. | $34.61 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $24.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.